These stocks are very promising, but it's important to consider the downside, too. Things aren't so bad for investors right now. We are in a bull market even though the economy is still having some problems. However, this bull run won't last forever. There will be a slowdown, equities will fall, and many won't deliver anything approaching decent returns for years after. So it's important to find stocks that can beat the market (hopefully by a large margin) over the long run. That's not easy to do, but here ...

Recursion Pharmaceuticals (RXRX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this biotechnology company have returned +17.9%, compared to the Zacks S&P 500 composite's +6.1% change. During this period, the Zacks Medical - Drugs industry, which Recursion Pharmaceuticals falls in, has gained 7.1%. The key question now is: What could be the stock's futu ...

Financial Data and Key Metrics - The company ended Q1 with nearly $300 million in cash, providing a robust runway for future milestones [13] Business Line Data and Key Metrics - The company has multiple Phase 2 trial starts and readouts planned for 2024 and the next 18 months, with a roughly quarterly cadence [11] - The company has identified exciting targets in non-small cell lung cancer through its collaboration with Tempus and is integrating larger chunks of their data for broader pan-cancer causal AI models [12] - The company has sequenced its one millionth transcriptome and is leveraging this data to build a comprehensive transcriptomic map [6] Market Data and Key Metrics - The company is expanding internationally with the opening of a London office, aiming to tap into the computational biology talent pool in the UK [20][26] - The company has a strong presence in Salt Lake City, Toronto, Montreal, and San Jose, with plans for further international growth in the intermediate to long term [58][59] Company Strategy and Industry Competition - The company is focused on building a TechBio platform that integrates multiple layers of omics data, including phenomics, transcriptomics, proteomics, and enviromics, to drive drug discovery [6][43][44] - The company is leveraging active learning to optimize experimentation, achieving 80% of the information value with only 40% of the experiments [7] - The company has built a supercomputer, BioHive 2, in partnership with NVIDIA, which is one of the fastest in biopharma, enhancing its computational capabilities [9][45][46] - The company is collaborating with Roche-Genentech, Bayer, and Helix, with potential for additional partnerships in non-oncology areas like cardiovascular and metabolism [5][41][49][50] Management Commentary on Operating Environment and Future Outlook - The company believes it is uniquely positioned to lead the TechBio evolution, with a robust pipeline, platform, and team [34][39] - The company expects to demonstrate the potential of its drug discovery philosophy through a variety of catalysts in the coming quarters and years [48] - The company is moving towards autonomous discovery, where AI agents will automatically hypothesize about biology and prioritize experimentation for faster impact on patients [51] Other Important Information - The company has hired Najat Khan, a former J&J executive, as Chief R&D Officer and Chief Commercial Officer, bringing extensive experience in drug discovery and digital tools [10] - The company has announced a collaboration with Helix to access large-scale population genomics and transcriptomics data, which will be integrated with its internal data for broader disease understanding [5][42] - The company is exploring the use of organoids and steroids to improve translation and predictive ADME Tox at scale, and is working on automated synthesis to accelerate small molecule development [52] Summary of Q&A Session Question: What does success look like for upcoming Phase 2 trial readouts? - Success will be measured by meaningful biological changes that benefit patients, with next steps including aggressive pursuit of moving medicines to patients, potentially moving to Phase 3 trials or discussions about accelerated approval [14][15][16] Question: How significant is the Phase 2 readout for REC-994 in validating the platform? - The Phase 2 readout for REC-994 is a key milestone, but the company emphasizes that each program is technically uncorrelated, with successes and failures expected across the pipeline [55][56] Question: What success has been achieved with Tempus data? - The company has already identified a novel opportunity in non-small cell lung cancer using Tempus data and is refining its AI models to integrate this data with proprietary data for target identification [19][57] Question: Why is the company opening a London office? - The London office is aimed at accelerating computational biology talent acquisition, leveraging the UK's strong training in data science and biology [20][26][58] Question: How does the company view competition from Xaira? - The company welcomes competition and collaboration, believing that the primary bottleneck in TechBio is data, and that companies with high-quality datasets will make rapid progress [27][60] Question: Will the company help labs working on ultra-rare diseases like Batten disease? - The company is open to working with patient groups and labs on rare diseases, leveraging its biological maps to advance programs, though immediate solutions may not be available [21][28][61] Question: What are the next big pieces needed for faster drug discovery? - The company believes that deep, broad datasets are critical for understanding biology and accelerating drug discovery, with a focus on integrating multiple omics layers and technologies [29][62][63]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4099738 (State or othe ...

May 2024 Disclaimers This presentation and any accompanying discussion and documents contain information that includes or is based upon "forward-looking statements" within' Litigation Reform Act of 1995. These for ward-looking statements are based on our current expectations, estimates and projections about our industry and ou and certain assumptions we have made. The words "plan," "anticipate," "believe," "continue," "extimate," "expect," "intend," "may," "will" and similar express forward-looking statemen ...

Washington, D.C. 20549 FORM 10-K (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 Recursion Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpo ...

Financial Data and Key Metrics Changes - The company reported nearly $400 million in cash at the end of 2023, indicating a healthy balance sheet moving into 2024 [79] - The company did not provide near-term revenue guidance but emphasized the potential for significant collaborations with partners like Bayer and Roche-Genentech [52][113] Business Line Data and Key Metrics Changes - The company has five Phase 2 programs either enrolling or soon to enroll patients, focusing on capital-efficient niche areas of biology [9] - The integration of the Cyclica team was completed in just 90 days, leading to advancements in the company's programs shortly after the acquisition [12][13] Market Data and Key Metrics Changes - The company has access to over 50 petabytes of proprietary biological and chemical data, which includes patient data from a partnership with Tempus [20] - The company is leveraging partnerships with major players like Roche-Genentech and Bayer to enhance its platform and pipeline [10][63] Company Strategy and Development Direction - The company aims to lead the TechBio space by creating a virtuous cycle of learning and iteration through its Recursion OS, which integrates data and technology [8][28] - The company is focused on building a robust internal pipeline while also pursuing significant partnerships to address high unmet needs in various therapeutic areas [113][114] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the potential for significant advancements in drug discovery and development through their innovative platform [132][138] - The company acknowledges the challenges in the biopharma industry but believes that their approach will lead to a fundamental transformation over the next decade [109][117] Other Important Information - The company has developed the fastest supercomputer in the biopharma space, which is expected to enhance its predictive capabilities [31][62] - The company has generated over 1 trillion neuronal iPSC cells since 2022, positioning itself as a leading producer in this area [64] Q&A Session Summary Question: How do you plan to utilize LOWE either internally or as an external offering? - The company sees LOWE as a tool for collaboration with partners and to drive progress through its pipeline [80] Question: What proof points can you share on AI, ML, and medicine? - The company highlighted its partnership with Roche-Genentech as one of the largest in TechBio, demonstrating the potential of AI in drug discovery [94] Question: What is the backlog of projects that are in the pipeline for AI analysis? - The company aims to meet or exceed industry averages in terms of success probability and efficiency in drug development [95] Question: When will the company be profitable? - The company plans to focus on growth while managing capital effectively, with a long-term view of significant opportunities in the biopharma space [141][142] Question: What is the company vision? - The vision is to digitize the biopharma space, moving from wet lab to dry lab, where experiments validate predictions made at scale [143] Question: What can you guide on the upcoming CCM readout? - The company is excited about the potential of the CCM program and sees it as a candidate for commercialization if the data is positive [151]

Q Recursion. certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from thir. company's own internal estimates and research. While the company believes these third-party sources to be reliable as of this p ndependently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained f ddition, all of the market data included in this presentation involves a number of assumpti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4099738 (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4099738 (State or other ...